The Lancet paper's problems are so numerous that I'm confident it will be retracted; however, what will the mainstream media do with all of this. They already reported the negative study. Will they report the retraction? How badly will this hurt the recruitment of patients for planned HCQ studies.
On a positive note, there was an encouraging study of HCQ plus zinc and Antibiotic out of New York, NYU!
"...zinc sulfate increased the frequency of patients being discharged home, and decreased the need for ventilation, admission to the ICU, and mortality or transfer to hospice for patients who were never admitted to the ICU.
"Conclusion: This study provides the first in vivo [human patients] evidence that zinc sulfate in combination with hydroxychloroquine may play a role in therapeutic management for COVID-19.
This following page has a list of doctor using HCQ plus zinc.
Early Adopters of Hydroxychloroquine + Zinc in the Media https://osf.io/qw54t/wiki/Early-Adopters/
Dr. Vladimir Zelenko is far and away the leading early adopter
“Hydroxychloroquine, 200 milligrams twice a day, five days. Azithromycin, 500 milligrams once a day, five days. Zinc sulfate, 220 milligrams once a day for five days.”
I think the following is consistent with the video presentation.
"In addition to the well-known functions of chloroquine such as elevations of endosomal pH, the drug appears to interfere with terminal glycosylation of the cellular receptor, angiotensin-converting enzyme 2. This may negatively influence the virus-receptor binding and abrogate the infection, with further ramifications by the elevation of vesicular pH, resulting in the inhibition of infection and spread of SARS CoV at clinically admissible concentrations." https://virologyj.biomedcentral.com/articles/10.1186/1743-422X-2-69
Yale Epidemiology Professor Urges Hydroxychloroquine & Azithromycin Early Therapy for COVID-19 5-28-20
“Available evidence of efficacy of HCQ+AZ has been repeatedly described in the media as “anecdotal,” but most certainly is not [merely anecdotal].” Professor Harvey Risch
“Some people will have contraindications and will need other agents for treatment or to remain in isolation. But for the great majority, I conclude that HCQ+AZ and HCQ+doxycycline, preferably with zinc can be this outpatient treatment, at least until we find or add something better, whether that could be remdesivir or something else.” http://covexit.com/yale-epidemiology-professor-urges-hydroxychloroquine-azithromycin-early-therapy-for-covid-19/